Background: Survivors of childhood non-Hodgkin lymphoma (NHL) are at increased risk for
limitations, existing data suggest that NHL survivors, compared to sibling controls, experience higher mortality, as well as performance limitations and health conditions that interfere with work or school attendance. 4, 6 The ability to discriminate late-occurring health conditions in NHL survivors will provide primary care and specialty clinicians tasked with managing long-term survivorship care with the knowledge necessary for early detection and attenuation of acquired risk factors. Therefore, our objective was to characterize late chronic health conditions, neurocognitive deficits, and physical performance limitations among a clinically evaluated cohort of adult survivors of childhood NHL.
PROCEDURE

Study population
Following informed consent, participants were enrolled in the St. Jude Lifetime Cohort Study (SJLIFE), an institutional review board approved study designed to ascertain health outcomes in adult childhood cancer survivors. Detailed study methods have been described. 7 Briefly, eligible subjects for this analysis were ≥ 18 years old, treated for NHL at St. Jude Children's Research Hospital (SJCRH), and survived ≥ 10 years after diagnosis. Cumulative treatment exposures (including chemotherapy and radiation doses to individual anatomic sites) and medical events during and after therapy were abstracted from medical records. All survivors underwent a core assessment comprising a history and physical examination, including measurement of resting heart rate and blood pressure, laboratory studies (complete blood cell count with differential, comprehensive metabolic panel, fasting lipid profile, insulin, glycosylated hemoglobin, thyroid stimulating hormone, free thyroxine, luteinizing hormone, follicle stimulating hormone, testosterone [male], estradiol [female] , and urinalysis), and a comprehensive physical performance assessment (measurement of body composition and neuromuscular system integrity). Participants completed comprehensive questionnaires providing demographic and intervening medical history data. In addition, participants underwent comprehensive risk-based medical evaluations (echocardiography, pulmonary function testing, semen analysis, and cataract assessment) and neurocognitive testing on the SJCRH campus as per guidelines endorsed by the Children's Oncology Group. 8, 9 As a result of early observation of cognitive impairment in SJLIFE, neurocognitive testing has evolved since the outset of the cohort such that it has now become part of the universal assessment.
Outcomes
Primary outcomes were chronic health conditions whose severity was classified as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 10 Graded conditions are defined in Supplementary Table S1 .
Chronic health conditions occurring prior to evaluation and subsequent neoplasms (SNs) were validated by medical record and pathology review.
Three neurocognitive domains were assessed in individuals at risk for neurocognitive impairment related to previous cancer treatment 8 :
( ) . Impairment was defined as ≥ 1 and < 2 standard deviations (SDs) (Grade 1, mildly impaired), ≥ 2 and < 3 SD (Grade 2, moderately impaired), and ≥ 3 SD (Grade 3, severely impaired) below the mean age-adjusted population normative score on any one measure. Moderate impairment, falling below the lowest 3rd percentile for population norms, would be expected to impact instrumental activities of daily living (reading, writing), while severe impairment, falling below the lowest 0.3 percentile for population norms, would be expected to impact self-care activities of daily living (e.g., bathing and taking medications). One individual developed subsequent neurologic injury associated with neurocognitive impairment unrelated to cancer therapy and was excluded from the analyses of neurocognitive function.
Six functional status outcomes were assessed: (1) aerobic function (6-min walk test 15, 16 ), (2) strength (maximal hand grip 17 and peak isokinetic torque of the quadriceps at 60°/sec 18 ), (3) muscular endurance (peak isokinetic torque of the quadriceps at 300°/sec 18 ), (4) flexibility (sit and reach test 19 and ankle dorsiflexion range of motion 20 ), (5) balance (sensory organization test 21 ), and (6) mobility (Timed Up and Go test 22 ). Body composition was measured using waist-to-height ratio and percent fat from dual-energy X-ray absorptiometry. 23 Functional impairments were not considered as chronic conditions and therefore not assigned a CTCAE grade. Assessments falling below the lowest 10th percentile for population normative data were considered abnormal and would be expected to impact instrumental activities of daily living (e.g., shopping for groceries or clothes).
Statistical analysis
Two-sample t-tests and 2 statistics were used to compare demographic and treatment-related characteristics between participants and eligible nonparticipants. Data for which < 10% of a given outcome was missing were considered missing at random unless otherwise stated. Grades 1 and higher chronic conditions were considered clinically significant and included in relevant statistical analyses. Exceptions included hypertension, hypothyroidism, glucose intolerance, stroke, and motor and sensory neuropathies, for which ≥ Grade 2 was considered clinically significant. Predictors of interest for clinically significant chronic conditions and abnormal physical performance scores were selected a priori based on evidence from existing literature. Multivariable models were constructed for prevalent outcomes, retaining variables with a P-value ≤ 0.1 on univariate analysis. For rare outcomes (decreased ejection fraction, abnormal pulmonary function, hypogonadism, neuropathy), univariate analyses were conducted.
Poisson regression models with robust error variance were used to model all chronic and physical performance outcomes.
Increased incidence of each SN was determined by first dividing the cohort into sex-, age-, race-, and calendar-year-specific categories consistent with those for which incidences are described by the Surveillance, Epidemiology, and End Results data to calculate the person-time. Person-time at risk for SNs was calculated from 1 year after the diagnosis of NHL until diagnosis of SN, death, or last followup. Standardized incidence ratios (SIRs) were calculated by dividing the number of observed SNs by the number of expected SNs.
RESULTS
Participants
Of 362 eligible NHL survivors, 200 (55%) underwent clinical assessments as of October 30, 2013 (Supplementary Fig. S1 ). Participants were more likely to be female, younger, and fewer years from childhood cancer diagnosis than nonparticipants (Table 1) 
Chronic conditions
The frequencies and severity of chronic conditions are listed in Table 2 .
The most prevalent included overweight/obesity (65%), elevated fasting glucose (37%), high total cholesterol (35%), and hypertension (25%). An additional 37% had evidence of prehypertension (Grade 1 hypertension). Among 164 individuals with a history of cardiotoxic therapies who underwent cardiac screening, 19 (12%) had cardiomyopathy, of which seven (4%) were Grades 3-4.
Adjusted models, retaining variables significant after univariate analyses, were used to identify associations with chronic conditions for which the number of events was sufficient (Supplementary Table   S2 ). Of note, current age (relative risk [RR] 1.1, 95% confidence interval [CI]: 1.1-1.1, P < 0.01) and body mass index ≥ 30 (RR 2.9, 95% CI:
1.6-5.3, P < 0.01) were associated with an increased risk for hypertension. Current age (RR 1.04, 95% CI: 1.0-1.1, P < 0.01) and abdominal radiation (RR 1.6, 95% CI: 1.1-2.4, P = 0.01) were associated with an increased risk for high total cholesterol, while individuals of non-white race were at decreased risk (RR 0.2, 95% CI: 0.1-0.9, P = 0.04) for the same. Similarly, current age (RR 1.03, 95% CI: 1.0-1.1, P < 0.01), body mass index ≥ 25 and < 30 (RR 1.5, 95% CI: 0.9-2.4, P = 0.02), body mass index ≥ 30 (RR 2.0, 95% CI: 1.2-3.1, P = 0.02), and abdominal radiation (RR 1.9, CI: 1.3-2.8, P < 0.01) were associated with having elevated fasting glucose. Lastly, those of non-white race (RR 1.4, 95% CI: 1.1-1.8, P < 0.01) and who received cranial radiation (CRT; RR 1.2, 95% CI: 1.0-1.5, P = 0.04) were at increased risk for overweight/obesity, while females were at decreased risk for the same (RR 0.7, 95% CI: 0.5-0.9, P < 0.01) compared to males. After excluding those who received cranial or abdominal radiation, 62% were overweight/obese, 29% had elevated fasting glucose, 30% had high total cholesterol, and 20% had hypertension. and who received gonadal radiation (RR 2.2, 95% CI: 1.4-3.6, P < 0.01) were at risk for oligospermia/azoospermia compared to those treated with < 4,000 mg/m 2 CED and without radiation, respectively (Supplementary Table S2 ). Table S2 ).
Subsequent neoplasms
Twenty-one individuals developed 48 SNs (median 2, range: 1-10), 12 (57%) ≥Grade 3. Cancers for which incidences are not described by the Surveillance, Epidemiology, and End Results data were excluded from SIR calculations (nonmelanoma skin cancers [27 basal cell carcinomas and three squamous cell carcinomas]). Overall, NHL survivors developed SNs at six times the expected rate of corresponding de novo cancers in the general population (observed/expected 6.3, 95% CI: 3.7-9.9) ( Table 3 ). All occurred in previously irradiated individuals. Following adjustment for variables significant in univariate analyses (relapsed disease), exposure to CRT (RR 2.4, 95% CI: 1.1-5.2, P = 0.03) and older attained age (RR 1.1, 95% CI: 1.06-1.14, P < 0.01) were associated with having an SN compared to those not exposed to CRT and younger survivors, respectively.
Neurocognitive impairment
Among participants who underwent comprehensive neurocognitive assessments (n = 171), 68% experienced at least mildly impaired executive function (≥Grade 1), attention, and/or memory ( Table 2) .
Forty-nine percent (n = 78/160) had Grades 1-3 impaired executive function, 30% (n = 49/159) attention, and 35% (n = 56/158) memory (Fig. 1) . Although a minority experienced moderately to severely impaired (Grades 2-3) executive function (18%), attention (15%), 
TA B L E 1 Participant and nonparticipant characteristics
Psychiatric symptoms
Participants were universally evaluated (n = 200) for anxiety, depression, and suicide ideation/attempt (Table 2) . No significant predictors were identified for anxiety. Following multivariable adjustment, female sex (RR 2.2, 95% CI: 1.0-4.8, P = 0.04), exposure to CRT (RR 3.3, 95%
CI: 1.4-7.8, P < 0.01), and cumulative corticosteroid exposure (RR 1.1, 95% CI: 1.0-1.2, P = 0.02) were significantly associated with depression. Those of older attained age (RR 0.9, 95% CI: 0.9-1.0, P = 0.04)
were less likely to have experienced suicide ideation/attempt than those of younger age, and females were three times more likely than males to experience suicide ideation/attempt (RR 3.0, 95% CI: 1.0-8.9, P = 0.04).
Physical function
Survivors exhibited physical performance deficits across all domains (Fig. 2) . Following multivariable adjustment, obesity (RR 2.4, 95% CI:
1.2-4.8, P = 0.03) and cardiac radiation (RR 2.5, 95% CI: 1.1-5.4, P = 0.02) were associated with risk for decreased aerobic function, and obesity was associated with decreased mobility (RR 2.1, 95% CI: 1.3-3.5, P < 0.01) ( Table 4) . Twenty-three survivors (11.5%) were unable to complete the muscular endurance segment of the physical function testing due to medical restrictions (n = 21) or scheduling error (n = 2). Similar to previous studies evaluating the burden of chronic conditions in cancer survivors, 9 we identified a high prevalence of specific conditions in aging NHL survivors, especially those cardiovascular risk factors well described within the context of the metabolic syndrome (hypertension, dyslipidemia, obesity, and elevated blood glucose). 25 A number of studies have reported a high prevalence of the metabolic syndrome in childhood cancer survivors. 26 Among survivors of other hematologic malignancies, the prevalence ranges from 6% to 34%, strongly associated with cranial and abdominal radiation. [27] [28] [29] Meacham and colleagues previously observed no difference in the prevalence of obesity between survivors and siblings (20.6% vs. 20.8%
DISCUSSION
reported a BMI ≥ 30 kg/m 2 , respectively); however, survivors, including those of NHL, were more likely than siblings to self-report taking medication for hypertension and dyslipidemia. 29 In contrast, 35% of our NHL survivors were identified as obese. Additionally, we identi- Neurocognitive screening has evolved within SJLIFE, initially as a risk based to now a universal screening approach, therefore not all participants have completed screening.
e Four of eight surgical (one at diagnosis and three during long-term follow-up). VC, vital capacity; FEV1, forced expiratory volume in 1 second; SN, subsequent neoplasm. a No significant associations identified for muscular endurance. Balance abnormality was only associated with non-white race (RR 3.6, 95% CI: 1.9-6.7) after univariate analyses. b Variables with a P-value ≤ 0.1 on univariate analysis were retained in multivariable analyses. * P-value < 0.05.
TA B L E 3 Standardized incidence ratios (SIRs) of subsequent neoplasms (SNs) a
their occurrences remain particularly concerning given that four of five NHL survivors in our cohort received anthracycline chemotherapy, one of five received chest-directed radiotherapy, and two-thirds had prehypertension/hypertension. Hypertension alone, and in combination with one or more additional cardiovascular risk factors, has been shown to potentiate the risk for heart failure in those treated with anthracyclines, as well as the risk for heart failure, coronary artery disease, and valvular disease in survivors treated with chestdirected radiotherapy, 31 underscoring the additional risks associated with blood pressure and metabolic derangements in NHL survivors already at increased risk for cardiovascular diseases due to treatmentrelated exposures.
In addition to the identification of well-established cardiovascular risk factors, we are the first to report directly assessed physical performance outcomes for childhood NHL survivors. Many survivors experienced physical performance limitations (Fig. 2) . Hoffman and colleagues have suggested that survivors cannot overcome performance F I G U R E 2 Physical performance deficits among adult survivors of NHL deficits through routine exercise alone, leading to speculation that they may benefit from tailored interventions targeting physiological deficits. 32 Despite the inability to resolve measurable deficits, regular exercise has been shown to reduce the risk for cardiovascular events in Hodgkin lymphoma survivors. 33 Similar advantages may be possible in NHL survivors. Therefore, an early identification of performance limitations unrecognized by current screening practices may enhance the ability to optimally reduce modifiable cardiovascular risk factors in NHL survivors and represents an area for future investigation.
Reassuringly, our data demonstrate a low prevalence of hypothalamic, pituitary, and thyroid dysfunction, likely reflecting elimination of CRT from frontline NHL protocols. However, survivors treated with alkylating agents and/or gonadal radiation were at risk for gonadal (ovarian and testicular Leydig cell) failure, as well as oligospermia/ azoospermia among male survivors. Despite the elimination of radiation, alkylating agent exposure (CED) exceeding 4,000 mg/m 2 remains common in current frontline NHL protocols, 3 and newly diagnosed children will likely continue to incur a risk to future fertility.
Previous neurocognitive studies in survivors of childhood NHL are limited to self-reported outcomes. For example, Kadan-Lottick and colleagues observed that, despite the omission of CRT from treatment strategies, 13-20% of NHL survivors reported impaired task efficiency, memory, and emotional regulation compared to siblings. 34 Through direct neurocognitive assessment, we identified at least mild neurocognitive impairment in more than two-thirds of at-risk sur- 
